Fifty-eight patients with recurrent nasopharyngeal carcinoma in nasopharynx and/or regional areas were re-radiated from 1972 to 1979 after initial irradiation. 70.7% of the recurrence appeared within 3 years after initial treatment. 90.9% of the recurrent tumor disappeared after re-radiation. The 3-and 5-year survival rates were 29.3% (17/58) and 12.1% (7/58). The factors influencing the prognosis are: the interval between the treatment and the recurrence; dose of re-radiation; and initial stage of the primary lesions. The authors suggest that the dose of re-radiation should be 70 Gy/7 weeks.
Download full-text PDF |
Source |
---|
J Neurosurg Pediatr
January 2025
1Neurotology Unit, Department of Neurosurgery, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow; and.
Objective: The objective of this study was to discuss the characteristics of intracranial extension in patients with juvenile nasopharyngeal angiofibroma (JNA) and propose and an algorithm for its management.
Methods: A retrospective chart review of all patients with JNA who underwent operations between January 2013 and January 2023 was done, and those cases with intracranial extension categorized as stage IIIb, IVa, and IVb according to the Andrews modification of the Fisch staging classification were included in the study. Data were collected about age at presentation, symptoms, radiological findings, routes of intracranial extension, therapeutic management, and follow-up.
Cancer Immunol Immunother
January 2025
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Sichuan, 610041, Chengdu, China.
Background: Immune checkpoint inhibitors (ICIs) show optimal treatment effects on recurrent or metastatic nasopharyngeal carcinoma(R/M NPC). Nonetheless, whether metastatic sites impact ICIs efficacy remains unclear.
Methods: We performed a secondary analysis of R/M NPC patients treated with KL-A167, a programmed cell death-ligand 1(PD-L1) inhibitor, based on a multicenter, single-arm, phase II study from China between 2019 and 2021 years, which represents the first and most comprehensive analysis of the effectiveness of a PD-L1 inhibitor in patients who have been previously treated.
Oral Oncol
January 2025
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China. Electronic address:
Background: Immune-related adverse events (irAEs) have been associated with better therapeutic outcomes in patients receiving immune checkpoint inhibitors (ICIs) across various cancers. This study investigates the association between irAEs and ICI outcomes in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC).
Methods: A post hoc analysis was performed on 153 patients with R/M NPC who received anti-PD-L1 inhibitors between February 26, 2019, and January 13, 2021.
Sci Rep
December 2024
Department of Otolaryngology Head and Neck Surgery, Shijiazhuang People's Hospital, Shijiazhuang, Hebei Province, China.
One of the primary reasons for the failure of therapy in nasopharyngeal cancer (NPC) is radio resistance-related localized one, which may lead to tumor residuals or recurrences. Several studies have linked interleukin-10 (IL-10) to crucial functions in cancer development and response to therapy. Its function in NPC's radio resistance is, however, not well understood.
View Article and Find Full Text PDFCureus
November 2024
Otolaryngology - Head and Neck Surgery, Konkuk University Medical Center, Seoul, KOR.
A 31-year-old woman presented with intermittent otalgia in the right ear, reporting severe pain during flights. The patient denied performing habitual Valsalva maneuvers. Otoendoscopic examination revealed hyperectatic herniation of the posterior portion of the right tympanic membrane (TM).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!